Alopecia AreataNCT04239521
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
An observational study of Alopecia Areata and Depressive Episode, run by Momentum Data at 1 site in United Kingdom.
Trial summary
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder
- What is being tested?
- Exposure of interest (studies 2 & 3).
- How many people
- 51,955 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Oct 2020to 28 Nov 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: These studies will use routinely collected and collated data from the Royal College of General Practitioners Research and Surveillance Centre database to provide a broadly representative sample of the population of England.
Who may be able to join
- Patients contributing to Royal College of General Practitioners Research and Surveillance Centre(RCGP RCS) primary care database between January 1, 2009 and December 31, 2018, will be eligible for inclusion.
- Only patients aged ≥18 will be eligible for studies 2 and 3.
- Only patients aged ≥ 18 and ≤ 65 will be included in the unemployment and sick day analysis (study 2)
Who cannot join
- People with the alternative non-AA diagnoses.
- People with AA diagnosis within 6 months of registration.
- People with less than 1 year of follow up available
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.
Read the detailed description
The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA.
The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata.
The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA.
The overall purpose of the fourth study (Study 4) is to assess the incidence of common infections in adult patients diagnosed with AA relative to a control population of patients without AA.
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders, Atopic Dermatitis, Allergic Rhinitis
- Being tested
- Exposure of interest (studies 2 & 3).
- Keywords
- Alopecia areata, Common mental health conditions, Depression, Anxiety, Autoimmune disease, Atopic conditions, Epidemiology, Incidence, Prevalence, Infection
- Medical subject headings
- Alopecia Areata, Depressive Disorder, Anxiety Disorders, Dermatitis, Atopic, Rhinitis, Allergic, Asthma, Crohn Disease, Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exposure of interest (studies 2 & 3).Other
Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
| Study group | Role | What they receive |
|---|---|---|
| Cases | Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis. Receives: Other: Exposure of interest (studies 2 & 3). | |
| Controls | The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level. Receives: Other: Exposure of interest (studies 2 & 3). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study 1: The incidence of Alopecia Areata
The incidence of Alopecia areata within the study cohort during the study period
Measured: Overall during 2009-2018 inclusive
Study 1: The incidence of Alopecia Areata stratified by sociodemographic factors
This will comprise of the incidence of Alopecia Areata over the study period, by age group, gender, ethnicity, and Social Economic Status.
Measured: Overall during 2009-2018 inclusive
Study 1:The annual rate of primary care visits for people with Alopecia Areata.
The annual rate of visits to primary care for any reason within one year of diagnosis.
Measured: Within one year of diagnosis of Alopecia Areata
Study 1: Secondary care dermatology service utilisation
The percent of people reviewed in secondary care dermatology services within one year of diagnosis of Alopecia Areata
Measured: Within one year of diagnosis of Alopecia Areata
Study 2: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis
Prevalence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Study 2: Describe the incidence of common mental health conditions in adult patients with Alopecia Areata
Incidence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within two years of diagnosis of Alopecia Areata
Study 2: Describe the mental health medication treatment burden of adult patients diagnosed with Alopecia Areata.
This will comprise of the number of medications used to treat mental health conditions in patients diagnoses with Alopecia Areata. Antidepressant medication classes to be examined comprise; selective serotonin reuptake inhibitors and related medications (serotonin and norepinephrine reuptake inhibitors (SNRIs)), tricyclic antidepressants and related medications (tetracyclic antidepressant), and monoamine oxidase inhibitors. Anxiolytic medications to be examined comprise all benzodiazepines and other related medications indicated for use in anxiety states.
Measured: Within two years of diagnosis of Alopecia Areata
Study 2: Number of patients diagnosed with Alopecia Areata receiving mental health psychological intervention.
This will comprise of the number of psychological interventions used to treat mental health conditions in patients diagnoses with Alopecia Areata. Psychological interventions comprise of counselling, Cognitive Behavioural Therapy, and psychotherapy.
Measured: Within two years of diagnosis of Alopecia Areata
Study 3: Describe the prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis
Prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata in a contemporary real-world population at diagnosis compared with matched controls.
Measured: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Study 3: Describe the incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata.
Incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of a composite of common infections in adult patients with Alopecia Areata
Incidence of a composite of any common infection (composite comprising a diagnosis of: upper and lower respiratory tract infection, pneumonia, acute bronchitis, influenza, skin infection, urinary tract infection, genital infections, gastrointestinal infection, herpes simplex and herpes zoster) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata
Incidence of a composite of any viral infection (composite comprising a diagnosis of: influenza, herpes simplex and herpes zoster infections, bronchitis, and any upper respiratory tract infections specifically coded as being viral) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Secondary outcomes (16)
Study 1: Adjusted incidence rate ratios of Alopecia Areata within England by geographic region.
By region across England.
Measured: Overall during 2009-2018 inclusive
Study 2: Prevalence (percentage) of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder), by socio-demographic factors, in adult patients diagnosed with Alopecia Areata.
By age group, gender, ethnicity, and Social Economic Status.
Measured: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Study 2: Describe the burden of 'sick days' in adult patients diagnosed with Alopecia Areata relating to mental health conditions.
Sick days will be indicated by the issuing of Med 3 certification from primary care (Statement of Fitness for Work) certification.
Measured: Within one year of diagnosis of Alopecia Areata
Study 2: Describe the prevalence of unemployment in adult patients diagnosed with Alopecia Areata.
Unemployment will be identified using Read codes relating to unemployment recorded in the clinical record or the issuing of an Incapacity Benefit (IB113) or Employment and Support Allowance (ESA113) form.
Measured: Within one year of diagnosis of Alopecia Areata
Study 4: The incidence of upper respiratory tract infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of upper respiratory tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of lower respiratory tract infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of lower respiratory tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of influenza infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of influenza or influenza-like illness (where direct swab confirmed diagnosis is not performed) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of acute bronchitis in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of acute bronchitis in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of pneumonia in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of pneumonia in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of gastrointestinal infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of gastrointestinal infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of stool confirmed gastrointestinal infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of gastrointestinal infection confirmed by stool culture or microscopy results (or other microbiological diagnosis confirmation) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of skin infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of skin infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of urinary tract infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of urinary tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of genital infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of genital infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of herpes zoster infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of herpes zoster infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata
Incidence of any recorded diagnosis of herpes simplex infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Measured: Within five years of Alopecia Areata diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2020
- Study start1 Oct 2020
- Primary completion31 Mar 2022
- Study completion28 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Alopecia AreataStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 51,955 participants (actual)
Sponsor and investigators
- Lead sponsor
- Momentum Data
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Pfizer, University of Surrey, University of Oxford
- Responsible party
- Sponsor
- Investigators
- Andrew McGovern, MD, Study director, Momentum Data
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04239521
- Sponsor's protocol ID
- P005
- Status last verified
- Dec 2022
- First submitted
- 9 Jan 2020
- Last updated
- 15 Dec 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual patient data is confidential but can be made available in an anonymised form to bone fide researchers subject to the required data protection training and other requirements. All data will remain behind a firewall and will only be available for access through a secured computer network.
Publications
Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, Messenger AG, Thompson AR. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022 Jul;187(1):73-81. doi: 10.1111/bjd.21055. Epub 2022 May 11.
PubMed 35157313Harries M, Macbeth AE, Holmes S, Thompson AR, Chiu WS, Gallardo WR, Messenger AG, Tziotzios C, de Lusignan S. Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series. BMJ Open. 2021 Nov 16;11(11):e045718. doi: 10.1136/bmjopen-2020-045718.
PubMed 34785540
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata
- ClinicalTrials.gov ID
- NCT04239521
- Acronym / sponsor ID
- P005
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders, Atopic Dermatitis, Allergic Rhinitis
- Keywords
- Alopecia areata, Common mental health conditions, Depression, Anxiety, Autoimmune disease, Atopic conditions, Epidemiology, Incidence
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51,955 participants (actual)
- Lead sponsor
- Momentum DataIndustry (pharma, biotech, devices)
- Collaborators
- Pfizer, University of Surrey, University of Oxford
- Study start
- 1 Oct 2020 (actual)
- Primary completion
- 31 Mar 2022 (actual)
- Study completion
- 28 Nov 2022 (actual)
- First posted
- 27 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.
Detailed description
The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA.
The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata.
The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA.
The overall purpose of the fourth study (Study 4) is to assess the incidence of common infections in adult patients diagnosed with AA relative to a control population of patients without AA.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases | – | Other: Exposure of interest (studies 2 & 3).Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis. |
| Controls | – | Other: Exposure of interest (studies 2 & 3).The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level. |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- These studies will use routinely collected and collated data from the Royal College of General Practitioners Research and Surveillance Centre database to provide a broadly representative sample of the population of England.
Key inclusion criteria (3 listed)
- Patients contributing to Royal College of General Practitioners Research and Surveillance Centre(RCGP RCS) primary care database between January 1, 2009 and December 31, 2018, will be eligible for inclusion.
- Only patients aged ≥18 will be eligible for studies 2 and 3.
- Only patients aged ≥ 18 and ≤ 65 will be included in the unemployment and sick day analysis (study 2)
Key exclusion criteria (3 listed)
- People with the alternative non-AA diagnoses.
- People with AA diagnosis within 6 months of registration.
- People with less than 1 year of follow up available
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exposure of interest (studies 2 & 3).Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis | Other | Cases, Controls |
Primary outcome
Study 1: The incidence of Alopecia Areata
Time frame: Overall during 2009-2018 inclusive
The incidence of Alopecia areata within the study cohort during the study period
Study 1: The incidence of Alopecia Areata stratified by sociodemographic factors
Time frame: Overall during 2009-2018 inclusive
This will comprise of the incidence of Alopecia Areata over the study period, by age group, gender, ethnicity, and Social Economic Status.
Study 1:The annual rate of primary care visits for people with Alopecia Areata.
Time frame: Within one year of diagnosis of Alopecia Areata
The annual rate of visits to primary care for any reason within one year of diagnosis.
Study 1: Secondary care dermatology service utilisation
Time frame: Within one year of diagnosis of Alopecia Areata
The percent of people reviewed in secondary care dermatology services within one year of diagnosis of Alopecia Areata
Study 2: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis
Time frame: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Prevalence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with Alopecia Areata in a contemporary real-world population compared with matched controls.
Study 2: Describe the incidence of common mental health conditions in adult patients with Alopecia Areata
Time frame: Within two years of diagnosis of Alopecia Areata
Incidence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Study 2: Describe the mental health medication treatment burden of adult patients diagnosed with Alopecia Areata.
Time frame: Within two years of diagnosis of Alopecia Areata
This will comprise of the number of medications used to treat mental health conditions in patients diagnoses with Alopecia Areata. Antidepressant medication classes to be examined comprise; selective serotonin reuptake inhibitors and related medications (serotonin and norepinephrine reuptake inhibitors (SNRIs)), tricyclic antidepressants and related medications (tetracyclic antidepressant), and monoamine oxidase inhibitors. Anxiolytic medications to be examined comprise all benzodiazepines and other related medications indicated for use in anxiety states.
Study 2: Number of patients diagnosed with Alopecia Areata receiving mental health psychological intervention.
Time frame: Within two years of diagnosis of Alopecia Areata
This will comprise of the number of psychological interventions used to treat mental health conditions in patients diagnoses with Alopecia Areata. Psychological interventions comprise of counselling, Cognitive Behavioural Therapy, and psychotherapy.
Study 3: Describe the prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis
Time frame: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata in a contemporary real-world population at diagnosis compared with matched controls.
Study 3: Describe the incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata.
Time frame: Within five years of Alopecia Areata diagnosis
Incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Study 4: The incidence of a composite of common infections in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Incidence of a composite of any common infection (composite comprising a diagnosis of: upper and lower respiratory tract infection, pneumonia, acute bronchitis, influenza, skin infection, urinary tract infection, genital infections, gastrointestinal infection, herpes simplex and herpes zoster) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Incidence of a composite of any viral infection (composite comprising a diagnosis of: influenza, herpes simplex and herpes zoster infections, bronchitis, and any upper respiratory tract infections specifically coded as being viral) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls.
16 secondary outcomes
Study 1: Adjusted incidence rate ratios of Alopecia Areata within England by geographic region.
Time frame: Overall during 2009-2018 inclusive
Study 2: Prevalence (percentage) of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder), by socio-demographic factors, in adult patients diagnosed with Alopecia Areata.
Time frame: At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive
Study 2: Describe the burden of 'sick days' in adult patients diagnosed with Alopecia Areata relating to mental health conditions.
Time frame: Within one year of diagnosis of Alopecia Areata
Study 2: Describe the prevalence of unemployment in adult patients diagnosed with Alopecia Areata.
Time frame: Within one year of diagnosis of Alopecia Areata
Study 4: The incidence of upper respiratory tract infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of lower respiratory tract infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of influenza infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of acute bronchitis in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of pneumonia in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of gastrointestinal infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of stool confirmed gastrointestinal infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of skin infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of urinary tract infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of genital infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of herpes zoster infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata
Time frame: Within five years of Alopecia Areata diagnosis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2022.
- Derived from this study: PubMed 35157313Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, Messenger AG, Thompson AR. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022 Jul;187(1):73-81. doi: 10.1111/bjd.21055. Epub 2022 May 11.
- Derived from this study: PubMed 34785540Harries M, Macbeth AE, Holmes S, Thompson AR, Chiu WS, Gallardo WR, Messenger AG, Tziotzios C, de Lusignan S. Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series. BMJ Open. 2021 Nov 16;11(11):e045718. doi: 10.1136/bmjopen-2020-045718.
- Individual participant dataSharing planned: Yes. Individual patient data is confidential but can be made available in an anonymised form to bone fide researchers subject to the required data protection training and other requirements. All data will remain behind a firewall and will only be available for access through a secured computer network.
Related trials for Alopecia Areata
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew McGovern, MD study director
Momentum Data
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alopecia Areata and Depressive Episode, run by Momentum Data at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Study 1: The incidence of Alopecia Areata (time frame: Overall during 2009-2018 inclusive). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04239521, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2022.